Company Description
LumiraDx Limited operates as a point of care diagnostics company.
The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers.
It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions.
Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease.
The company is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,210 |
Contact Details
Address: 3 More London Riverside London, X0 SE1 2AQ United Kingdom | |
| Phone | 011 44 1786 430411 |
Stock Details
| Ticker Symbol | LMDXF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001685428 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Veronique Ameye EMBA, Esq., M.B.A. | Chief Executive Officer and General Counsel |
| Dorian LeBlanc CPA | Chief Financial Officer and Vice President of Global Operations |
| Colleen McMillen | Vice President of Communications |
| Andy Ward | National Sales Director - UK |
| David Walton DMS | Chief Commercial Officer |
| Giffin Daughtridge | President of North America Commercial Operations and Global Molecular Solutions |
| Melissa Garcia | Vice President and Corporate Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2024 | 25-NSE | Filing |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | 6-K | Report of foreign issuer |
| Dec 29, 2023 | 6-K | Report of foreign issuer |
| Dec 29, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 26, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 20, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 11, 2023 | 6-K | Report of foreign issuer |
| Nov 21, 2023 | 6-K | Report of foreign issuer |